S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:DAREDare Bioscience Stock Price, Forecast & News

$1.14
-0.03 (-2.56 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.13
Now: $1.14
$1.17
50-Day Range
$0.99
MA: $1.13
$1.52
52-Week Range
$0.69
Now: $1.14
$2.22
Volume571,098 shs
Average Volume1.13 million shs
Market Capitalization$30.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in San Diego, California.
Read More
Dare Bioscience logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.02 per share

Profitability

Net Income$-14,260,000.00

Miscellaneous

Employees5
Market Cap$30.70 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$1.14
-0.03 (-2.56 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

How has Dare Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Dare Bioscience's stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DARE shares have increased by 12.9% and is now trading at $1.14.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Dare Bioscience?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Dare Bioscience
.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Dare Bioscience
.

How were Dare Bioscience's earnings last quarter?

Dare Bioscience Inc (NASDAQ:DARE) posted its earnings results on Wednesday, August, 12th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.13.
View Dare Bioscience's earnings history
.

What price target have analysts set for DARE?

5 brokers have issued 12-month target prices for Dare Bioscience's shares. Their forecasts range from $3.00 to $7.50. On average, they anticipate Dare Bioscience's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 294.7% from the stock's current price.
View analysts' price targets for Dare Bioscience
.

Has Dare Bioscience been receiving favorable news coverage?

News coverage about DARE stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dare Bioscience earned a news impact score of -1.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Dare Bioscience
.

Are investors shorting Dare Bioscience?

Dare Bioscience saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 263,100 shares, an increase of 52.6% from the June 15th total of 172,400 shares. Based on an average daily trading volume, of 390,000 shares, the short-interest ratio is presently 0.7 days.
View Dare Bioscience's Short Interest
.

Who are some of Dare Bioscience's key competitors?

What other stocks do shareholders of Dare Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dare Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Novavax (NVAX), SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Gilead Sciences (GILD), Vaxart (VXRT), Heat Biologics (HTBX) and Micron Technology (MU).

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the following people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 52)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 60)
  • Mr. Mark Walters, VP of Operations (Age 64)
  • Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 43)
  • Dr. David Friend, Chief Scientific Officer

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Who are Dare Bioscience's major shareholders?

Dare Bioscience's stock is owned by many different retail and institutional investors. Top institutional investors include Founders Financial Securities LLC (0.36%), Virtu Financial LLC (0.15%) and HighTower Advisors LLC (0.10%).
View institutional ownership trends for Dare Bioscience
.

Which institutional investors are buying Dare Bioscience stock?

DARE stock was purchased by a variety of institutional investors in the last quarter, including Founders Financial Securities LLC, Virtu Financial LLC, and HighTower Advisors LLC.
View insider buying and selling activity for Dare Bioscience
.

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.14.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $30.70 million. The biotechnology company earns $-14,260,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.

What is Dare Bioscience's official website?

The official website for Dare Bioscience is www.darebioscience.com.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.